Autophagy in inflammation, infection, and immunometabolism

Immunity, Journal Year: 2021, Volume and Issue: 54(3), P. 437 - 453

Published: March 1, 2021

Language: Английский

---

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

JAMA Oncology, Journal Year: 2016, Volume and Issue: 2(10), P. 1354 - 1354

Published: June 29, 2016

The presence of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in breast cancer, and TILs may synergize with chemotherapy immune checkpoint inhibitor therapy for improved clinical response. A more detailed understanding the variation lymphocytic infiltration cancer aid identifying subtypes amenable to immunomodulation.To determine median percentage patients no, intermediate, or high levels TIL assess variations cell subsets across subtypes.Eligible studies (PubMed, 1990-2015) analyzed tumor lymphocytic, CD8+, FOXP3+ cellular infiltrates, used multivariable analyses quantitative methods enumerating populations. Selection was performed accordance PRISMA guidelines evaluated by 2 independent appraisers.Fifteen (n = 13 914) met prespecified criteria were reviewed December 2015. 11% (range, 5%-26%) cancers demonstrate lymphocyte-predominant (LPBC), approximately 16% showing no evidence TILs. Triple-negative (TN) demonstrated highest incidence LPBC (20%; range, 4%-37%). This similar that are human epidermal growth positive either hormone receptor negative (HER2+) at (range 11%-24%). Hormone positive/HER2- (HR+) showed lowest 6% 3%-12%). CD8+ T-cell indicative type I immunity, found 48% all 32%-80%) observed TN (60%; 40%-91%) HER2+ disease (61%; 40%-83%). Fewer HR+ tumors (43%; 30%-73%). cells (70%; 65%-76%) (67%; 61%-74%). minority (38%; 35%-41%).The magnitude variable within between subtypes. Levels subpopulations identify immunomodulation indicate additional strategies enhance immunity low moderate

Language: Английский

---

Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS

Cell, Journal Year: 2019, Volume and Issue: 178(1), P. 176 - 189.e15

Published: May 30, 2019

Language: Английский

---

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: Feb. 5, 2021

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted differentiation, recent evidence suggests that their crosstalk regulates exhaustion immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show contributes to persistence of

Language: Английский

---

Linking cellular stress responses to systemic homeostasis

Nature Reviews Molecular Cell Biology, Journal Year: 2018, Volume and Issue: 19(11), P. 731 - 745

Published: Oct. 10, 2018

Language: Английский

---